Skip to Main Content

Scrambling to contain investor unrest, Mylan is sparring with a big shareholder advisory firm over a report concerning the pay package given its non-executive chairman, Robert Coury, as well as his role at the beleaguered drug maker.

In a June 6 letter to Institutional Shareholder Services, several Mylan board members objected to the firm’s decision not to share its report before it is distributed to its clients. And they chided ISS for its unwillingness to acquiesce during a meeting that took place on Monday, according to their letter, which was filed with the U.S. Securities and Exchange Commission.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!